United States Patent 8,101,599: Scope, Claims, and Competitive Patent Landscape

US Patent 8,101,599 claims fixed-dose combination and kit formats comprising valsartan + amlodipine + hydrochlorothiazide (HCTZ) with defined dosage ranges and an amlodipine besylate limitation. The claim set targets three commercialization routes that matter for generics and pipeline entrants: (1) single-tablet/capsule fixed-dose combinations, (2) multi-unit kits where components are dosed as separate units that may optionally be combined, and (3) instruction-guided therapeutic use spanning broad cardiometabolic indications and selected CNS/other indications.

What is claimed in the composition claims (independent + dependent structure)?

Independent claim (1) covers a pharmaceutical composition containing:

Valsartan (or a pharmaceutically acceptable salt)
Amlodipine (or a pharmaceutically acceptable salt)
Hydrochlorothiazide (or a pharmaceutically acceptable salt)

Each component must be present in a “pharmaceutically effective amount.” Claim 2 then narrows to a fixed dose combination, and claim 3 narrows further to tablet or capsule.

Independent structure and narrowing logic

Claim 1: composition with three actives (open-ended within “effective amount”)
Claim 2: fixed dose combination
Claim 3: tablet or capsule format
Claims 4–11: numerical dosage windows for each component
Claims 12–16: amlodipine must be in besylate salt form (for specific dosage embodiments)

Key coverage dimensions

Form factor
- Tablet/capsule fixed dose (claims 2–3)
Quantitative dose ranges
- Broad to narrow windows across multiple dose tiers (claims 4–6) and specific point doses (claims 7–11)
Salt form
- Amlodipine besylate is required for multiple embodiments (claims 12–16)
Scope through “pharmaceutically effective amount”
- Even if numeric ranges do not map perfectly, claim 1 retains broad conceptual coverage unless the defendant product stays outside the effective amount framework

What are the exact dosage ranges and discrete dose embodiments (composition)?

Claims 4–6 provide ranges; claims 7–11 lock discrete dose trios.

Dosage ranges (claim 4)

Valsartan: about 20 to 640 mg
Amlodipine: about 1 to 60 mg
HCTZ: about 5 to 200 mg

Dosage ranges (claim 5)

Valsartan: about 40 to 320 mg
Amlodipine: about 2.5 to 10 mg
HCTZ: about 5 to 25 mg

Dosage ranges (claim 6)

Valsartan: about 160 to 320 mg
Amlodipine: about 5 to 10 mg
HCTZ: about 12.5 to 25 mg

Discrete dose embodiments (claims 7–11)

Claim	Valsartan (mg)	Amlodipine (mg)	HCTZ (mg)
7	about 160	about 10	about 12.5
8	about 160	about 10	about 25
9	about 320	about 10	about 25
10	about 160	about 5	about 12.5
11	about 160	about 5	about 25

Salt restriction tied to discrete embodiments (claims 12–16)

Claim 12: claim 7 + amlodipine besylate
Claim 13: claim 8 + amlodipine besylate
Claim 14: claim 9 + amlodipine besylate
Claim 15: claim 10 + amlodipine besylate
Claim 16: claim 11 + amlodipine besylate

Practical impact: the salt limitation is not optional for those enumerated dose points. A generic that uses a different amlodipine salt could avoid claims 12–16 but may still fall within claims 1–11 unless salt differences do not matter for infringement of earlier claims (not enough claim language is provided here to narrow beyond what you supplied).

How broad are the kit claims, and where do they change infringement risk?

Independent claim (17) covers a kit with:

A dose unit for valsartan
A dose unit for amlodipine
A dose unit for HCTZ
And “wherein two of said dose units can optionally take the form of a single dose unit.”

That optional combining language matters: it covers both:

three separate pills (three dose units), and
two-in-one plus one separate, including combinations where two actives share a single dose unit (for example, a two-drug tablet plus a third separate unit).

Claim 18 requires amlodipine besylate for the kit.

Claims 19–26 provide the same dose windows and discrete dose points as the composition claims, expressed as “amount present in one of said dose units.”

Dose windows (kit)

Mirrors claims 4–6:
- claim 19: valsartan 20–640 mg, amlodipine 1–60 mg, HCTZ 5–200 mg
- claim 20: valsartan 40–320 mg, amlodipine 2.5–10 mg, HCTZ 5–25 mg
- claim 21: valsartan 160–320 mg, amlodipine 5–10 mg, HCTZ 12.5–25 mg
Discrete dose triads mirrored in claims 22–26:
- (160/10/12.5), (160/10/25), (320/10/25), (160/5/12.5), (160/5/25)

What is the “instructions” limitation, and how far does it reach?

Claims 27–30 add a further kit feature: instructions that guide use for one of two disease groups.

Claim 27 instruction scope

Instructions cover guidance for use in either:

(A) treatment of or delaying onset of a long cardiometabolic and vascular list including:
- hypertension, peripheral edema, heart failure, congestive heart failure, left ventricular dysfunction, hypertrophic cardiomyopathy, diabetic cardiac myopathy, supraventricular arrhythmia, ventricular arrhythmia, atrial fibrillation, atrial flutter, detrimental vascular remodeling, myocardial infarction, sequelae of myocardial infarction, atherosclerosis, angina, renal insufficiency, angina pectoris, diabetes, secondary aldosteronism, pulmonary hypertension, renal failure
(B) management of a list of other conditions including:
- migraine, peripheral vascular disease, Raynaud’s disease, luminal hyperplasia, cognitive dysfunction, glaucoma, stroke

Claims 28–30 narrow to subsets

Claim 28: instructions for hypertension and peripheral edema
Claim 29: instructions for hypertension
Claim 30: instructions for peripheral edema

Practical impact for enforcement: the instruction claims are not limited to “physician use” language provided here, but the scope is tied to what the kit instructions guide. A kit supplier that avoids including specific instruction content could argue non-infringement against claims 27–30 even if component dosing matches.

What does this mean for design-around strategies?

Based strictly on the claim content you provided, design-around pivots cluster around three controllable levers.

1) Avoid matching the dose trios

The claims include both ranges and point doses. A product outside:

the broad range (claim 4), or
the intermediate range (claim 5), and
the narrower range (claim 6), could reduce risk against the dependent dosage claims. Claim 1 still uses “effective amount,” so dose avoidance must be paired with a clear separation from “effective amount” coverage to matter.

2) Avoid fixed-dose tablet/capsule format

If the product is exclusively packaged as separate components without the “fixed dose combination” definition being met (claim 2–3), then only the kit route (claim 17 onward) may remain relevant.

3) Salt form engineering for amlodipine

Claims 12–16 (composition) and 18 (kit) require amlodipine besylate for those salt-tied embodiments. If a product uses a different pharmaceutically acceptable salt of amlodipine, it can avoid those specific dependent claim paths. It may still be exposed to earlier, non-salt-limited claims (claim 1, claim 2, claim 3, claim 4–11, and claim 17 without claim 18).

Where does US 8,101,599 sit in the broader patent landscape for the same drug combination?

Given only the claim text you supplied, the landscape interpretation is limited to structural inference, not to file histories or cited documents. The claim set is concentrated on:

the therapeutic combination (valsartan + amlodipine + HCTZ),
packaging formats (single fixed-dose unit vs kit),
specific dosing regimes that align with common clinical dose steps for these agents,
and at least one salt specification (amlodipine besylate).

Landscape takeaways (based on claim scope)

Any competitor offering the same three actives in a single fixed-dose tablet/capsule is within the strongest claim path (claims 1–3 plus likely 4–11 if dose-matched).
Any competitor offering a kit that includes three dose units with a two-in-one option is within claim 17, even without fixed-dose co-formulation.
Instruction content can be a trap: kits that include instructions tailored to hypertension/peripheral edema or broader lists could trigger claims 27–30.
Salt form matters for certain dependent embodiments: amlodipine besylate constraints attach to specific dosage points (composition) and to the kit (claim 18).

Key Takeaways

US 8,101,599 covers valsartan + amlodipine + HCTZ in both fixed-dose tablets/capsules and kits with optional combining of two dose units into a single unit (claims 1–3, 17).
The claims include explicit dose ranges and discrete dose combinations (claims 4–11, 19–26) that likely match typical clinical titration steps.
Amlodipine besylate is required in multiple dependent embodiments for both composition and kit (claims 12–16, 18).
The kit claims add an additional infringement lever through instruction-guided therapeutic use, including broad cardiometabolic indications and narrower hypertension/peripheral edema subsets (claims 27–30).

FAQs

Does US 8,101,599 require a single tablet containing all three drugs?
No. It covers both a fixed-dose tablet/capsule composition (claims 2–3) and a kit with separate dose units where two can optionally be combined (claim 17).
What amlodipine salt does the patent require in key dependent claims?
Amlodipine besylate is required for specific composition dose points (claims 12–16) and for the kit (claim 18).
Are the dosage ranges only approximate, or are there exact dose points?
Both. Claims include ranges (claims 4–6 for composition; 19–21 for kit) and specific dose trios (claims 7–11 for composition; 22–26 for kit).
Can a kit avoid infringement by changing packaging format?
Shifting away from the claimed kit structure (three dose units with two optionally combined) and avoiding the specific instruction content could reduce exposure, but the independent kit claim (17) is broad on structure.
How do the instruction claims affect product differentiation?
Claims 27–30 attach liability to what the kit instructions guide for specified conditions; kits that avoid those instruction sets could reduce risk for that claim tier.

References

[1] U.S. Patent No. 8,101,599 (claim text provided in prompt).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	040014	⤷ Start Trial
Austria	429223	⤷ Start Trial
Australia	2003240261	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,101,599

Summary for Patent: 8,101,599